Royalty Pharma plc
RPRX · CIK 0001802768 · Industry not specified
About Royalty Pharma plc
Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
Business information sourced from SEC annual filing filed Feb 11, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Financial highlights
Latest qualifying annual SEC observations · USDHistorical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| No qualifying annual financial data available. | ||||||||
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Company information
- Registered name
- Royalty Pharma plc
- Ticker symbol
- RPRX
- CIK
- 0001802768
- Exchange
- Not available
- Industry
- Not available
- SEC SIC code
- Not available
- Fiscal year end (MMDD)
- Not available
- Last SEC synchronization
- Not synchronized
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Official website, business descriptions and executive details require separate verification.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| No filings imported yet. | |||
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.